- Home
- HTO vs NEO Comparison
HTO vs NEO Comparison
Compare HTO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | NEO |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Precision Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 1994 | 2008 |
Fundamental Metrics
Financial Performance| Metric | HTO | NEO |
|---|---|---|
| Price | $64.09 | $16.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $62.00 | $13.38 |
| AVG Volume (30 Days) | 341.9K | ★ 2.3M |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 1.74 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $800,590,000.00 | N/A |
| Revenue This Year | $10.26 | $10.63 |
| Revenue Next Year | $7.06 | $9.73 |
| P/E Ratio | $129.65 | ★ N/A |
| Revenue Growth | ★ 6.97 | N/A |
| 52 Week Low | $43.75 | $6.24 |
| 52 Week High | $67.09 | $16.92 |
Technical Indicators
Market Signals| Indicator | HTO | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 57.82 |
| Support Level | $55.76 | $11.49 |
| Resistance Level | $63.28 | $16.92 |
| Average True Range (ATR) | 1.19 | 0.56 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 77.04 | 55.70 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.